Atomo’s all-in-one RDT platforms put the end user first and make it easy to test and screen for a range of infectious diseases and chronic conditions.
Their unmatched usability has won the respect of frontline healthcare providers worldwide, and has made Atomo the OEM partner of choice for diagnostic manufacturers looking to transform their RDT offerings.
Atomo Diagnostics is a specialist medical device design innovator and original equipment manufacturing (OEM) company whose unique proprietary technologies support usability, accuracy, and safety. Headquartered in Sydney, Australia, Atomo has emerged as a global leader in the development of point of care devices for rapid diagnostic testing (RDT).
Atomo’s operations are ISO 9001 and ISO 13485 certified for the design, development, and manufacture of in vitro diagnostic medical devices.
Atomo’s device solutions address challenges associated with in-field deployment of standard RDT kits. The focus on usability and simplicity in design means Atomo’s integrated RDT platforms are easy to learn and teach, and suitable for use in a variety of real world settings, including doctor’s offices, pharmacies, point of care settings, community clinics, and the home.
AtomoRapid™ RDT platforms are customisable to suit a variety of blood-based lateral flow test assays and are appropriate for a range of applications, including screening for chronic conditions and detection of infectious diseases.
It’s a sign of how well Australia has handled the coronavirus pandemic that a single positive case in the community will make national headlines, while in many other countries thousands of people are dying from the disease every day. Our hotel quarantine system for......
Researchers at NSF International and Novateur Ventures screen rapid-detection COVID-19 tests for clinical sensitivity/specificity, limit of detection and time to results After screening more than 1,100 independently assessed, point-of-care COVID-19 tests, researchers at NSF International and Novateur Ventures have identified 5 direct (antigen/RNA) tests......
Dozens of public and private sector employers are now offering rapid testing to those without symptoms. Businesses and public sector organisations are joining a government scheme to test workers without symptoms who cannot work from home. Around 1 in 3 people who have coronavirus......
